The past several years have witnessed a resurgence of interest in classic psychedelics (e.g., psilocybin, LSD, DMT) and empathogens/entactogens (e.g., MDMA) for their potential therapeutic applications in a range of psychiatric conditions, including major depressive disorder, treatment-resistant depression, PTSD, and substance use disorders. Although psilocybin and MDMA are now in late-stage FDA regulatory clinical trials, there is still a paucity of adequately powered, randomized, controlled data on the efficacy, tolerability and safety of these approaches. Major unresolved issues include the role of “set and setting” and non-drug factors in the potential benefit of these approaches, and the optimal delivery of psychedelic-assisted psychotherapy for patients. This webinar brings together several leading experts to provide their clinical and research perspectives on the psychedelic medicine field as it pertains to depression, anxiety, and PTSD.
A leading academic psychiatry expert (Dr. Carhart-Harris) will serve as keynote speaker and discuss the state of the science for psilocybin in depression, including a discussion of its history, neuropsychopharmacology, clinical effects, and safety.
This keynote lecture will be followed by a panel discussion including leading clinical and research faculty experts in classic psychedelics and MDMA (Drs. Fonzo, Yehuda, and Ross) who will discuss emerging scientific, clinical, and regulatory challenges for the field.
Attendees of this interactive webinar will have the opportunity to engage with the faculty and will gain a better understanding of the complex problems and potential opportunities that psychedelics pose for clinical practice.
- To describe the neuropsychopharmacology and mechanisms of actions of several classic psychedelics and empathogens
- To review the strengths and limitations of recent clinical trials of psilocybin and MDMA for patients with treatment-resistant depression and PTSD, respectively
- To discuss challenges for clinicians in the adoption and implementation of psychedelic-assisted psychotherapy
Keynote Presentation | Psychedelics: Brain Mechanisms
Presented by Robin Carhart-Harris, PhD
This talk will take a multi-level view of the brain action of classic psychedelic drugs, i.e., drugs that share the property of activating the serotonin 2A receptor. Beginning at the receptor level, it moves through a developmental and evolutionary understanding of serotonergic functioning and brain plasticity, placing emphasis on the context dependency of responses to classic psychedelic compounds. It will review the dynamic, whole-brain action of psychedelics and how this relates to knowledge of the development and evolution of global brain function and anatomy. It couches our understanding of the therapeutic action of psychedelic therapy within a predictive coding framework and reviews recent trial and imaging results from a double-blind randomized controlled trial of psilocybin therapy vs escitalopram for depression.
Panel Discussion | Psychedelic Therapy: Problems and Promises
Expert Panelists: Greg Fonzo, PhD, Stephen Ross, MD, and Rachel Yehuda, PhD
The panel discussion will bring together several clinical and research faculty experts in classic psychedelics and MDMA (Drs. Fonzo, Yehuda, and Ross) to discuss emerging scientific, clinical, and regulatory challenges for the field. Attendees of this interactive webinar will have the opportunity to engage with the faculty and will gain a better understanding of the complex problems and potential opportunities that psychedelics pose for clinical practice.
Discounted rates available for students, professional in developing countries, and members of the media.